<?xml version="1.0" encoding="UTF-8"?>
<p id="Par16">Although cardiac involvement usually occurs later in the course of COVID-19, acute HF secondary to myocardial involvement or previously existing cardiac disease could be the presenting symptoms in COVID-19 infection in almost one-quarter of patients. The management of myocardial dysfunction in COVID-19 leading to HF is similar to other forms of HF. Optimization of fluid balance, monitoring of electrolytes and renal function, and early use of the cardiac catheterization laboratory and invasive monitoring all play important roles in managing COVID patients with HF [
 <xref ref-type="bibr" rid="CR58">58</xref>].
</p>
